The Role of the Core Imaging Laboratory in Multicenter Trials

References 

1. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology. 2005;64:208–215
   • CrossRef
2. Ravina B, Tanner C, Dieuliis D, et al. A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. Mov Disord. 2009;24:2081–2090
   • CrossRef
3. Marek K, Jennings D, Tamagnan G, et al. Biomarkers for Parkinson's disease: tools to assess Parkinson's disease onset and progression. Ann Neurol. 2008;64(suppl 2):S111–S121
   • CrossRef
4. Seibyl J, Jennings D, Tabamo R, et al. The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease. Minerva Med. 2005;96:353–364
   • MEDLINE
5. Walhovd KB, Fjell AM, Brewer J, et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol. 2010;31:347–354
   • CrossRef
6. Jack CR, Bernstein MA, Fox NC, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685–691
   • CrossRef
7. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310–1323
   • CrossRef
8. Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. Neuroimage. 2009;46:154–159
   • CrossRef
9. Haense C, Herholz K, Jagust WJ, et al. Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (nest-DD and ADNI). Dement Geriatr Cogn Disord. 2009;28:259–266
   • CrossRef
10. Zubal IG, Early M, Yuan O, et al. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients. J Nucl Med. 2007;48:857–864
    • MEDLINE
    • CrossRef
11. Code of Federal Regulations Title 21 Food and Drugs: Parts 1-1499, Part 11-Electronic Records; Electronic Signatures. 1997;